Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | TTR | P02766 | 1/20 | 0.32 |
| ▸ | IL2 | P60568 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13643860 | 0.88 | OPRK1 (0.40) | OPRK1POLBKMT2AMEN1MAPT | |
| SCHEMBL18643482 | 0.87 | OPRK1 (0.42) | OPRK1POLBKMT2AMEN1MAPT | |
| SCHEMBL13643858 | 0.86 | THRB (0.36) | POLBKMT2AMEN1MAPTRXFP1 | |
| SCHEMBL13643859 | 0.86 | OPRK1 (0.38) | OPRK1POLBKMT2AMEN1MAPT | |
| SCHEMBL13644616 | 0.86 | TP53 (0.39) | POLBKMT2AMEN1MAPTRXFP1 | |
| SCHEMBL4397934 | 0.85 | OPRK1 (0.45) | OPRK1POLBKMT2AMEN1MAPT | |
| SCHEMBL13644622 | 0.84 | OPRK1 (0.37) | OPRK1POLBKMT2AMEN1MAPT | |
| SCHEMBL4400114 | 0.83 | POLB (0.39) | OPRK1POLBKMT2AMEN1MAPT | |
| SCHEMBL13644623 | 0.82 | OPRK1 (0.38) | OPRK1POLBKMT2AMEN1MAPT | |
| SCHEMBL18643375 | 0.81 | OPRK1 (0.38) | OPRK1POLBKMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2793928-B1 | PROCESS FOR PURIFYING A SAMPLE OF H38C2 ANTIBODY | PFIZER (US) | 2017-03-15 | — | — | EP | disclosed |
| US-9163227-B2 | Anti-diabetic compounds | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2015-10-20 | — | — | US | disclosed |
| US-9163227-B2 | Anti-diabetic compounds | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2015-10-20 | — | — | US | disclosed |
| US-8722622-B2 | FGF21 conjugates and anti-diabetic uses thereof | COVX TECHNOLOGIES IRELAND, LIMITED (IE) | 2014-05-13 | — | — | US | disclosed |
| US-8722622-B2 | FGF21 conjugates and anti-diabetic uses thereof | COVX TECHNOLOGIES IRELAND, LIMITED (IE) | 2014-05-13 | — | — | US | disclosed |
| WO-2013093720-A2 | ANTI-DIABETIC COMPOUNDS | PFIZER INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20130164310-A1 | ANTI-DIABETIC COMPOUNDS | COVX TECHNOLOGIES IRELAND LIMITED | 2013-06-27 | — | — | US | disclosed |
| US-20130164310-A1 | ANTI-DIABETIC COMPOUNDS | COVX TECHNOLOGIES IRELAND LIMITED | 2013-06-27 | — | — | US | disclosed |
| US-20120282279-A1 | Anti-Diabetic Compounds | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2012-11-08 | — | — | US | disclosed |
| US-20120282279-A1 | Anti-Diabetic Compounds | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2012-11-08 | — | — | US | disclosed |
| WO-2012059873-A2 | ANTI-DIABETIC COMPOUNDS | COVX TECHNOLOGIES IRELAND, LTD. (IE) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120282279-A1 | Anti-Diabetic Compounds | GLP1R, FGF2, FGFR1 | OPRK1 4623/4885POLB 4521/4885KMT2A 3880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.